Kite Pharma Reports Third Quarter 2014 Results SANTA

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Kite Pharma Reports Third Quarter 2014 Results

SANTA MONICA, Calif., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq: KITE ), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2014.

"This has been an exciting quarter for Kite and our collaborators at the National Cancer Institute (NCI), as we continue to make substantial progress with our clinical programs, including our lead product candidate, KTE-C19," said Dr. Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. "Clinical data presented this quarter in both The Lancet and The Journal of Clinical Oncology further validate the growing body of support for the role of CAR-T cell immunotherapy in the treatment of B-cell lymphomas and leukemias."

Dr. Belldegrun continued, "We have a busy few months ahead of us, focusing on the achievement of clinical and regulatory milestones as we approach year-end and move into 2015. Additionally, we have oral presentations related to KTE-C19 scheduled to take place at the upcoming American Society of Hematology (ASH) meeting in San Francisco next month."    

Third Quarter 2014 Financial Results

For the third quarter ended September 30, 2014, Kite reported a net loss attributable to common stockholders of approximately $9.1 million, compared to a net loss attributable to common stockholders for the quarter ended September 30, 2013 of $2.1 million. Basic and diluted net loss per share for the quarter of 2014 was $0.24, compared to a net loss per share of $0.37 for the third quarter of 2013. Non-cash charges included $3.4 million related to stock based compensation.

Total operating expenses for the quarter ended September 30, 2014 were $9.1 million as compared to $1.5 million for the quarter ended September 30, 2013. This increase primarily related to stock-based compensation of $3.4 million, as well as additional headcount.

Research and development (R&D) expenses for the quarter ended September 30, 2014 were $5.7 million, compared to $1.2 million for the third quarter of 2013. This increase primarily related to stock-based compensation of $1.8 million, as well as additional R&D headcount to further the development of Kite's pipeline of eACT™-based product candidates.

General and administrative (G&A) expenses were $3.4 million for the quarter ended September 30, 2014, compared to $0.3 million for the same period in 2013. This increase primarily related to stock-based compensation of $1.6 million, as well as additional headcount.

On September 30, 2014, Kite had $195.4 million in cash, cash equivalents, and marketable securities. Kite had no outstanding debt as of September 30, 2014.

About Kite Pharma, Inc.

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing novel immunotherapies and other oncology treatments. Kite is based in Santa Monica, CA.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Kite may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Kite's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success and timing of the ongoing and anticipated clinical trials for Kite's current product candidates and the ability and willingness of the NCI to continue research and development activities relating to eACT™ pursuant to the CRADA. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail under the heading "Risk Factors" in the Form 10-Q for the quarter ended September 30, 2014. Any forward-looking statements that Kite makes in this press release speak only as of the date of this press release. Kite assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 
KITE PHARMA, INC.
CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
         
  THREE MONTHS ENDED NINE MONTHS ENDED
  SEPTEMBER 30, SEPTEMBER 30,
  2014 2013 2014 2013
Operating expenses:        
Research and development  $ 5,716  $ 1,167  $ 15,232  $ 3,189
General and administrative  3,385 339 8,172  839
Total operating expenses  9,101  1,506  23,404  4,028
Operating loss  (9,101)  (1,506)   (23,404)  (4,028)
Other income (expense):        
Interest income  61  22  129  31
Interest expense  —   —  (6,266)  (4)
Other income (expense)  (11)  (5)  (10)  13
Total other income (expense)  50  17  (6,147)  40
Net loss  (9,051)  (1,489)  (29,551)  (3,988)
Unrealized loss on available-for-sale securities, net (107) — (107) —
Comprehensive loss (9,158) (1,489) (29,658) (3,988)
Net loss (9,051) (1,489) (29,551) (3,988)
Series A Preferred Stock dividend  —   (563)  (1,089)  (866)
Net loss attributable to common stockholders  $ (9,051)  $ (2,052)  $ (30,640)  $ (4,854)
Net loss per share, basic and diluted  $ (0.24)  $ (0.37)  $ (1.76)  $ (0.89)
Weighted-average shares outstanding, basic and diluted  38,330,026  5,485,221  17,383,846  5,459,226
 
 
KITE PHARMA, INC.
CONDENSED BALANCE SHEETS
(In thousands)
     
  September 30, 2014 DECEMBER 31,
  (UNAUDITED) 2013
ASSETS    
Current assets    
Cash and cash equivalents  $ 79,022  $ 22,357
Marketable securities 116,371 —
Prepaid expenses  1,137  241
Total current assets  196,530  22,598
Property and equipment, net  1,612  274
Other assets  190  110
Total assets  $ 198,332  $ 22,982
LIABILITIES AND STOCKHOLDERS' EQUITY  
Current liabilities    
Accounts payable  $ 1,004  $ 382
Accrued expenses and other current liabilities  1,505  980
Options early exercise liability  1,079  —
Total current liabilities  3,588  1,362
Deferred rent  93  39
Options early exercise noncurrent liability  1,480  —
Total liabilities  5,160  1,401
Total stockholders' equity  193,172  21,581
Total liabilities and stockholders' equity  $ 198,332  $ 22,982

Kite Pharma Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson For Investor Inquiries: Kimberly Minarovich Burns McClellan 212-213-0006

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hone Health’s $228M Bet on Data-Led Longevity Care

Updated Category News Views 191

Longevity medicine just got a very large check and an even larger assignment. Hone Health says it has raised $228 million to push physician-led care beyond its roots in hormone optimization, and the split of that financing matters more than the celebrity names attached to it. Only $28 million is described as Series A equity; the other $200 million comes as growth...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 125

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 95

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
Airtel Money Upgrade Raises the Stakes in East Africa

Updated Category News Views 77

Mobile money lives or dies in the irritating little moments: a transfer that hangs, a menu that makes people punch five buttons too many, a merchant payment that simply will not clear. Airtel Money is attacking that friction in Malawi and Tanzania with an enhanced platform from Comviva, and this is more consequential than the usual software-refresh chest thumping. In...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 107

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 171

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 72

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 91

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 23

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 20

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Promising Industrials Stocks: AVAV, GMS, VRRM Insights

Updated Category News Views 190

Identifying Opportunities in the Industrials Sector In today's market, identifying oversold stocks in the industrials sector presents a golden opportunity for investors seeking undervalued assets. An oversold stock usually indicates that its price has dropped significantly, creating potential for future upward movement. Understanding the RSI Indicator The Relative...

Continue Reading
Florida Cancer Specialists Innovates Care with Navigation Program

Updated Category News Views 252

Florida Cancer Specialists Revolutionizes Oncology Navigation Florida Cancer Specialists & Research Institute, LLC (FCS) recently unveiled an intriguing case study that illustrates the profound impact of their patient navigation program. This initiative is structured under the Principal Illness Navigation (PIN) billing codes introduced by the Centers for Medicare &...

Continue Reading
Celebrating Creativity: ASCAP Composers' Choice Awards 2025

Updated Category News Views 267

ASCAP Honors Top Screen Composers for 2025 The American Society of Composers, Authors and Publishers (ASCAP) has recognized the incredible talent of top screen composers at the highly anticipated ASCAP Composers' Choice Awards for 2025. This event highlights the artists whose musical creations bring depth and emotion to films, TV series, and video games. The awards shine...

Continue Reading
Innovative Features of Catalogic's DPX vPlus Unveiled

Updated Category News Views 105

Enhancing Data Protection with DPX vPlus 7.0 Catalogic Software, a reputable provider of secure data protection solutions with over 25 years of experience, has recently launched an impressive upgrade to its enterprise data protection software: DPX vPlus 7.0. This new version is designed to meet the evolving needs of modern enterprise environments, offering significant...

Continue Reading
Legal Action Reminders for Investors in CAE, Inc.

Updated Category News Views 99

Investor Alert: Class Action Lawsuit Against CAE, Inc. ClaimsFiler is notifying investors about a significant legal case involving CAE, Inc. (NYSE: CAE). If you've experienced losses exceeding $100,000 from your investment in CAE, it's important to take action quickly to safeguard your rights. Overview of the Class Action Lawsuit This lawsuit claims that CAE and certain...

Continue Reading